Why did ALSEN.PA stock drop in pre-market on 24 Mar 2026?

ALSEN.PA stock fell **34.08%** on heavy volume. The drop followed clinical update headlines, but high selling volume suggests profit-taking or position adjustments rather than a single disclosed negative event.

What are the key financial metrics for ALSEN.PA stock to watch?

Monitor **EPS -0.09**, **PE -4.56**, **PB 2.77**, current ratio **4.59**, and cash per share **€0.16**. These show development-stage losses with decent short-term liquidity.

What is Meyka AI’s grade and recommendation for ALSEN.PA stock?

Meyka AI rates ALSEN.PA **66.79/100**, Grade **B**, suggestion **HOLD**. The grade balances liquidity and R&D potential against negative profitability and valuation risks.

What price targets and forecast apply to ALSEN.PA stock?

Scenario targets: Bear **€0.15**, Base **€0.27**, Bull **€0.80**. Meyka AI's yearly forecast is **€0.14**, implying roughly **-64.76%** from **€0.41**. Forecasts are model-based and not guarantees.

EU Stocks

Pre-Market: ALSEN.PA Sensorion SA down 34.08% on 24 Mar 2026: catalyst check

ByHuzaifa Zahoor March 24, 2026

ALSEN.PA stock plunged 34.08% to €0.41 in pre-market trading on 24 Mar 2026, making Sensorion SA one of the top losers on EURONEXT. The move came on 10,851,073.00 shares, well above the 3,0*294,657.00 average volume. Sensorion (ALSEN.PA) is a clinical-stage biotechnology company focused on inner ear therapies; the drop follows the company’s six-month follow-up release on its gene therapy program. We summarise drivers, key ratios, technicals and a model-based forecast to help frame the pre-market sell-off for European investors.